ArticleJournal of thoracic disease2026

Repurposing the MEK inhibitor binimetinib as a dual anti-inflammatory and antifibrotic agent in pulmonary fibrosis.

Yupei Zhang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.